Chronic Hand Eczema Clinical Trial
Official title:
Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO) - a Randomized Controlled Trial
This study is a multicentre, double-blinded, randomized, placebo-controlled, clinical trial with open-label extension. The purpose and aim of this study is to investigate the efficacy and safety of roflumilast (PDE4-inhibitor) in adult patients with chronic hand eczema (CHE). Patients will receive 16-week treatment with either roflumilast or placebo tablets. Hereafter, both groups continue in open-label treatment for 12 weeks where both groups will receive treatment with roflumilast.
This study will investigate the efficacy and safety of roflumilast in adult patients with CHE and it is hypothesized that patients treated with oral roflumilast (500 microgram once daily) will experience an improvement in their moderate-to-severe CHE (measured by hand eczema severity index (HECSI)) and alter the skin microbiome. Secondly, it is hypothesized that patients treated with oral roflumilast will experience improved lung function and weight loss. This study includes two phases: Phase 1: 20 patients will receive 500 microgram tablet of roflumilast once daily for 16 weeks while 20 patients will receive placebo once daily for 16 weeks. Phase 2: All 40 patients from phase 1 will receive 500 microgram tablet of roflumilast once daily for 12 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05545215 -
Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand Eczema
|
||
| Completed |
NCT05486117 -
Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
|
Phase 1 | |
| Recruiting |
NCT06004050 -
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
|
Phase 3 | |
| Recruiting |
NCT05994976 -
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
|
||
| Completed |
NCT03683719 -
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
|
Phase 2 | |
| Completed |
NCT04872101 -
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
|
Phase 3 | |
| Completed |
NCT01482663 -
Chronic Hand Eczema - Self-management and Prognosis
|
N/A | |
| Completed |
NCT04871711 -
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
|
Phase 3 | |
| Recruiting |
NCT05026554 -
Characterization of Chronic Hand Eczema
|
||
| Completed |
NCT05259722 -
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
|
Phase 3 | |
| Recruiting |
NCT03861455 -
Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
|
Phase 2 | |
| Recruiting |
NCT05355818 -
Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema
|
Phase 3 | |
| Completed |
NCT04949841 -
Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
|
Phase 3 | |
| Completed |
NCT03246776 -
Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan
|
Phase 4 | |
| Not yet recruiting |
NCT06283550 -
Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
|
Phase 2 | |
| Completed |
NCT04378569 -
Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
|
Phase 1/Phase 2 |